Creating Value Through Breakthrough Science

We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors

More Info
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers

Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

July 17, 2024
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution

Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and

Read More
July 9, 2024
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters

Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our

Read More
June 5, 2024
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. “We are excited by these

Read More
May 13, 2024
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study

Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, has announced the publication of its Phase 2 long COVID results in Clinical Infectious Diseases. The publication entitled “Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2

Read More
April 9, 2024
Finally, Graphene electronic devices available for all

Paragraf, the world’s only mass producer of graphene electronics using transfer-free graphene grown with conventional semiconductor processes, has opened a new online store to enable global access to its unique Graphene-based Field Effect Transistor (“GFET”). GFETs have a wide range of uses in the development of industry, medical, and chemical

Read More
April 4, 2024
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations

Phase Four, a leading provider of next generation electric propulsion (EP) solutions for satellites, has been awarded a $14.9M contract by the Defense Advanced Research Projects Agency (DARPA) to deliver an "air-breathing" EP system to enable extended satellite operations in Very Low Earth Orbit (VLEO), at altitudes as low as

Read More
March 26, 2024
Achronix FPGAs add support for Bluespec’s Linux-capable RISC-V Soft Processors to enable scalable processing

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Bluespec, Inc., an industry leader in RISC-V tools and silicon IP, has announced a family of Linux-capable RISC-V soft processors that are available for the Achronix Speedster®7t FPGA family. Marking an industry first, Bluespec’s RISC-V processors

Read More
March 11, 2024
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel

Read More
February 21, 2024
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, has announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD),

Read More
February 12, 2024
Resolve Therapeutics announces publication of Lupus clinical trial results

Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus

Read More
February 5, 2024
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC

Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet

Read More
December 21, 2023
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip

The European Investment Bank (EIB) and Novadip have signed a €18 million venture debt financing agreement supported by the European Union’s InvestEU initiative. The Belgian biotech company will use the funds to support clinical trials of NVD-003, an autologous bone product that provides one-time curative treatment to achieve long-term union

Read More
December 14, 2023
Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring

Repeated Signal Solutions, Inc. (RSS) and Avari Wireless Inc. have announced the launch of Enhanced ERCES Monitoring™.  Enhanced ERCES Monitoring™ is a new service that allows building owners to monitor their First Responder (ERCES) radio systems remotely with the same level of visibility as required by the NFPA code. "Enhanced

Read More
December 5, 2023
Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in

Read More
November 30, 2023
Avari Wireless awarded contract to provide radio communications coverage for the Toronto underground subway system pilot project

Avari Wireless has announced they are the winner of the tender to supply Distributed Antenna System (DAS) for the Toronto Transit Commission (TTC). The project’s scope is to supply engineering, equipment, materials, and other services to construct a Distributed Antenna System (DAS) using digital technologies, to provide radio communications coverage

Read More
November 10, 2023
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver

Read More
November 7, 2023
Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs

Zeotap Data, a leading provider of fully-consented, people-based data solutions, is proud to introduce Validated Demos the key to delivering reach and frequency metrics against your core demographic audience in programmatic media buying. Through exclusive partnerships with Europe’s major mobile telco operators, Zeotap Data employs cutting-edge modelling techniques to leverage

Read More
November 6, 2023
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a

Read More
October 17, 2023
NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that one of its novel Structural Engineered Fatty Acids (SEFAs), SEFA-6179, has been granted Rare Pediatric Disease (RPD) Designation by the United States Food and

Read More
October 11, 2023
Achronix announces FPGA-Powered accelerated Automatic Speech Recognition solution

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, is proud to announce its latest innovation in partnership with Myrtle.ai — an accelerated automatic speech recognition (ASR) solution based on the Speedster7t FPGA. This transformative solution converts spoken language to text in over 1,000 concurrent real-time

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

Greenwich

500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845

London

16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100